The Veterinary Renal Disease Market was valued at USD 16.88 billion in 2024, and is projected to reach USD 24.85 billion by 2030, rising at a CAGR of 6.70%. Rising prevalence of renal diseases coupled with adoption of therapeutic food as a treatment are key growth drivers for this market. Renal diseases like chronic kidney disease (CKD), renal failure, etc. cause irreversible damage to the renal system of animals. Despite no definite cure for this disease, proper management by various types of therapies can help in the betterment of animal life. One of the most prominent methods is that of nutritional management through therapeutic food.
Another crucial market propeller is the rising adoption of AI in veterinary renal disease diagnostics and treatment. Imaging plays a significant role in veterinary medicine by offering vital data for regular preventative measures as well as the assessment of disease and injury. AI can prove to be a very beneficial tool, especially in radiologist deficient geographies. Associated benefits such as faster and enhanced diagnostic capabilities is anticipated to increase adoption of AI and thereby influence positively on market in near future.
Mars Inc, which is a prominent player in the animal health space, has already stepped into the field of applying AI to veterinary diagnostics and treatment. Antech Diagnostics (Mars Inc.) introduced RenalTech, a cutting-edge diagnostic tool, in 2019. RenalTech uses artificial intelligence (AI) to evaluate pet medical record data and forecast a cat's risk of developing chronic kidney disease (CKD) up to two years ahead of an established clinical diagnosis.
Moreover, market dynamics such as product portfolio expansion, M&A, consolidation activities are further anticipated to provide growth platform to this market. For example, in September 2023, Elanco Animal Health received conditional U.S. FDA approval for Varenzin-CA1 (molidustat oral suspension), as the treatment to control non-regenerative anemia in cats with chronic kidney disease (CKD). Furthermore, in December 2023, Neogen Corporation partnered with the TerraNova Equestrian Center in Myakka City, Florida, making the company the official biosecurity provider of the facility for diagnostic testing products.
This product will be delivered within 2 business days.
Another crucial market propeller is the rising adoption of AI in veterinary renal disease diagnostics and treatment. Imaging plays a significant role in veterinary medicine by offering vital data for regular preventative measures as well as the assessment of disease and injury. AI can prove to be a very beneficial tool, especially in radiologist deficient geographies. Associated benefits such as faster and enhanced diagnostic capabilities is anticipated to increase adoption of AI and thereby influence positively on market in near future.
Mars Inc, which is a prominent player in the animal health space, has already stepped into the field of applying AI to veterinary diagnostics and treatment. Antech Diagnostics (Mars Inc.) introduced RenalTech, a cutting-edge diagnostic tool, in 2019. RenalTech uses artificial intelligence (AI) to evaluate pet medical record data and forecast a cat's risk of developing chronic kidney disease (CKD) up to two years ahead of an established clinical diagnosis.
Moreover, market dynamics such as product portfolio expansion, M&A, consolidation activities are further anticipated to provide growth platform to this market. For example, in September 2023, Elanco Animal Health received conditional U.S. FDA approval for Varenzin-CA1 (molidustat oral suspension), as the treatment to control non-regenerative anemia in cats with chronic kidney disease (CKD). Furthermore, in December 2023, Neogen Corporation partnered with the TerraNova Equestrian Center in Myakka City, Florida, making the company the official biosecurity provider of the facility for diagnostic testing products.
Veterinary Renal Disease Market Report Highlights
- Based on type, the treatment segment led the market with the largest revenue share of 68.96% in 2024, due to the wide array of treatments available coupled with ever growing population of pets globally
- Based on animal type, the feline segment is expected to grow at the fastest CAGR over the forecast period
- Based on route of administration, the oral segment held the largest revenue share in 2024 and the injectable segment is expected to have the fastest CAGR over the forecast period
- Based on the indication, the renal cystitis segment held the largest revenue share of 29.05% in 2024 and nephritis segment is expected to have the second fastest CAGR over the forecast period
- Rising prevalence of a variety of renal complications in animals, prominent usage of pet food, growing disease awareness initiatives are contributing to the market growth
- North America accounted for the largest revenue share of the market in 2024. The increasing significance of animal health care in general throughout the region has been identified as a key factor propelling market expansion. The American Pet Products Association estimates that 65.1 million homes in the country have pets in 2023-2024. Moreover, growing pet owners' awareness of animal health and the significance of providing care for animals with renal disorders are fueling the market expansion in North America
- In May 2024, Dechra Pharmaceuticals announced distribution rights of two products to support kidney health in senior cats - Porus One, and Add One. Porus One contains renaltec, a selective absorber that soaks up precursors of uremia toxins in the cat’s intestines that would ordinarily be removed or regulated by healthy kidneys. Add One is a moist cat treat designed for senior cats, developed to encourage them to eat Porus One, and is said to be useful for cats that prefer dry food
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Veterinary Renal Disease Market Variables, Trends, & Scope
Chapter 4. Veterinary Renal Disease Market: Product Type Estimates & Trend Analysis
Chapter 5. Veterinary Renal Disease Market: Animal Type Estimates & Trend Analysis
Chapter 6. Veterinary Renal Disease Market: Route of Administration Estimates & Trend Analysis
Chapter 7. Veterinary Renal Disease Market: Indication Estimates & Trend Analysis
Chapter 8. Veterinary Renal Disease Market: Distribution Channel Estimates & Trend Analysis
Chapter 9. Veterinary Renal Disease Market: Regional Estimates & Trend Analysis
Chapter 10. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies featured in this Veterinary Renal Disease market report include:- Mars, Incorporated
- Nestle Purina PetCare
- Arkray
- General Mills
- Zoetis Inc.
- Merck & Co., Inc.
- Elanco
- Bionote U.S.A
- Ceva Santé Animale
- Boehringer Ingelheim International GmbH
- Dechra Pharmaceuticals PLC
- Vedco Inc.
- Mission Pharmacal Company
- Neogen Corporation
- IDEXX Laboratories, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 150 |
Published | May 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 16.88 Billion |
Forecasted Market Value ( USD | $ 24.85 Billion |
Compound Annual Growth Rate | 6.7% |
Regions Covered | Global |
No. of Companies Mentioned | 16 |